4.2 Article

Association of CTLA-4 polymorphisms and clinical-immunologic characteristics at onset of type 1 diabetes mellitus in children

Journal

HUMAN IMMUNOLOGY
Volume 70, Issue 2, Pages 116-120

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.humimm.2008.12.007

Keywords

Type 1 diabetes; CTLA-4 polymorphism; Autoantibodies; Cytokines

Categories

Funding

  1. San Borja Arriaran Hospital
  2. Exequiel Gonzalez Cortes Hospital
  3. Roberto del Rio Hospital
  4. Chilean juvenile Diabetes Foundation
  5. FONDECYT [1060790]

Ask authors/readers for more resources

CTLA-4 is a homeostatic regulator of T cell activation and is believed to play a critical role in immune tolerance. Polymorphisms in the CTLA-4 promoter (-318C/T) and in exon 1 (+49 A/G) were analyzed in 300 Chilean patients with type 1 diabetes mellitus (T1D) and 310 healthy children by polymerase chain reaction-restriction fragment length polymorphism. The effect of CTLA-4 allele and haplotype frequencies on the interferon-gamma, tumor necrosis factor-a, and transforming growth factor-p, levels and the presence in serum of GAD65 and 1A-2 autoantibodies at the onset of T1D was evaluated. The distribution of the CTLA-4 allele and genotype frequencies was found to be similar in patients and control children. However, among the T1D patients' carriers of GG genotype on CTLA-4 gene a higher frequency of anti-GAD65 autoantibodies (87.2%) was observed. On the other hand, higher ketoacidosis at onset, younger age at onset, and higher levels of tumor necrosis factor-alpha and interferon-gamma were observed in T1D patients carriers of G allele in comparison with the carriers of AA genotype. In conclusion, the result of this study showed that CTLA-4 +49 A/G and -318 C/T polymorphisms were not linked with a higher genetic risk for T1D. However, the presence of a GG genotype or G allele dosage was associated with a younger age of onset, higher prevalence of ketoacidosis at the moment of diagnosis and positive anti-GAD65 serum autoantibodies. (c) 2009 Published by Elsevier Inc. on behalf of American Society for Histocompatibility and Immunogenetics.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available